In spite of advancements in all types of malignancy control like surgery, chemotherapy, radiotherapy, immunotherapy as well as presence of many peptides in the market for cancer control, prognosis in many types of cancer still very poor. It is enough for anybody to have a look at the main causes of death at any country to know that cancer is one of them and to discover how the challenge and defect in its treatment. Many researches aim was just the improvement of the already present methods. Here we introduce something new in the form of synthetic peptides derived from honey proteins that may overcome this challenge through direct apoptotic action on its own and not only limited to certain tumor cell line.Patent: WO/2014/040605. METHODS: to avoid any bias as being the owner of the patent, we preferred to do our experiments outside.So,the following experiments were done by Genscript company.Growth inhibitory assay was performed with 10ug, 25ug, 50ug, 75ug and 100ug of each peptide. (A+F) per well. Peptide A and peptide F were stored at -20℃. 5mg samples of peptide A and peptide F were dissolved in 500ul DPBS to make the stock solution which will be added into the wells directly. 1% TFA solution was applied as the control. a) Plate the cells into the 96 well assay plate in a density of 5000 and 10000 cells/well for adherent and suspension cell lines respectively with 50 μL complete cell culture medium. b) Add 10 μL stock solutions of the compounds into the wells. c) 10 μL 1% TFA solution was used as the control for data analyzing. d) Add 40 μL of complete medium into the wells to reach a total volume of 100μL. e) Incubate the plate at 37℃ for 72 hours. f) Add 50 μL Celltiter Glo assay mix solution to each well and mix gently at room temperature for 10 minutes, then read the luminescence with PherastarPlus (Molecular Devices). Results: In vitro studies showed inhibitory effects for those peptides by themselves upon about 17 tumor cell lines out of 18 cell lines; U87MG, MDA-MB-468, K562,A375, MG63, SH-4, RD, KP1, 5637, 2774, ML-1, Cal-27, Colo-205, 769P, EOL-1, HLE, MDA-MB-436 and Calu-3 as well as the case with in vivo study in U87MG tumor mouse model.Pharmacokinetic of peptide F was also studied using 3 rats that showed very shot half life. At the moment, we try to modify and improve peptide F and other peptides to get more potent effects plus safety. who knows, we may do it.So, it is clear how those results could move the field of malignancy in general and especially gliomas management forward.